MB 311

Drug Profile

MB 311

Latest Information Update: 12 Jun 2015

Price : $50

At a glance

  • Originator Meridian Biopharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Lewis Y antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 04 Jun 2015 MB 311 is still in phase I trials for Cancer in Austria and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top